

PEER-REVIEW REPORT

Name of journal: World Journal of Critical Care Medicine

Manuscript NO: 57287

Title: Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (cytoSorb®) in patients with sepsis and septic shock

Reviewer's code: 02446387

Position: Peer Reviewer

Academic degree: MHSc, PhD

Professional title: Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: India

Manuscript submission date: 2020-06-02

Reviewer chosen by: Jia-Ping Yan

Reviewer accepted review: 2020-06-19 18:54

Reviewer performed review: 2020-06-19 19:06

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The report on a prospective study of treatment effects of the CytoSorb® therapy used as an adjunctive therapy along with standard of care in Septic patients admitted to intensive care unit. Both primary and secondary outcomes were evaluated. The findings offer insightful details on the timing of the CytoSorb treatment and safety. Although the limitations are documented, the sample size is relatively small and may not be generalizable to other patients.